| acute coronary syndrome | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| CHAMPION-PLATFORM, 2009 | vs delayed clopidogrel | | | target vessel revascularization 0.72 [0.40; 1.30] stroke 1.15 [0.39; 3.43] MI 0.91 [0.75; 1.11] death, MI, stroke, or target vessel revascularization 0.87 [0.72; 1.05] | | CHAMPION-PCI, 2009 | vs delayed clopidogrel | | | target vessel revascularization 0.56 [0.28; 1.11] All cause death 1.59 [0.52; 4.86] MACE 0.67 [0.40; 1.14] stroke 0.85 [0.29; 2.53] MI 0.40 [0.12; 1.27] death, MI, stroke, or target vessel revascularization 1.04 [0.89; 1.22] |
| Trial | Treatments | Patients | Method |
|---|
| CHAMPION-PLATFORM, 2009 | cangrelor up front (cangrelor during PCI followed by 600 mg of clopidogrel) (n=2693) vs. delayed clopidogrel (placebo during PCI followed by 600 mg of clopidogrel) (n=2669) cangrelor up front vs delayed clopidogrel | patients with acute coronary syndrome undergoing percutaneous coronary intervention Patients with stable angina were initially eligible
at the beginning of the trial before a protocol
amendment | double blind Parallel groups Sample size: 2693/2669 Primary endpoint: death, MI, ischemia-driven revascularization FU duration: 48 h | | CHAMPION-PCI, 2009 | cangrelor up front (cangrelor administered before percutaneous coronary intervention and followed by clopidogrel) (n=4367) vs. clopidogrel up front (clopidogrel followed by placebo) (n=4355) cangrelor then clopidogrel vs clopidogrel then placebo | high risk patients requiring PCI | double blind Parallel groups Sample size: 4367/4355 Primary endpoint: death, MI, ischemia-driven revascularization FU duration: 48 h |
|
| percutaneous coronary intervention | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| CHAMPION-PLATFORM, 2009 | vs delayed clopidogrel | | | target vessel revascularization 0.72 [0.40; 1.30] stroke 1.15 [0.39; 3.43] MI 0.91 [0.75; 1.11] death, MI, stroke, or target vessel revascularization 0.87 [0.72; 1.05] | | CHAMPION-PCI, 2009 | vs delayed clopidogrel | | | target vessel revascularization 0.56 [0.28; 1.11] All cause death 1.59 [0.52; 4.86] MACE 0.67 [0.40; 1.14] stroke 0.85 [0.29; 2.53] MI 0.40 [0.12; 1.27] death, MI, stroke, or target vessel revascularization 1.04 [0.89; 1.22] | | CHAMPION PHOENIX, 2013 | vs delayed clopidogrel | MACE 0.80 [0.68; 0.94] MI 0.81 [0.68; 0.97] death, MI, stroke, or target vessel revascularization 0.80 [0.68; 0.94] net benefit 0.80 [0.68; 0.94] stent thrombosis 0.62 [0.43; 0.90] | | all bleeding 1.75 [0.73; 4.17] All cause death 1.00 [0.52; 1.92] Cardiovascular mortality 1.00 [0.52; 1.92] major bleeding 1.50 [0.53; 4.21] |
| Trial | Treatments | Patients | Method |
|---|
| CHAMPION-PLATFORM, 2009 | cangrelor up front (cangrelor during PCI followed by 600 mg of clopidogrel) (n=2693) vs. delayed clopidogrel (placebo during PCI followed by 600 mg of clopidogrel) (n=2669) cangrelor up front vs delayed clopidogrel | patients with acute coronary syndrome undergoing percutaneous coronary intervention Patients with stable angina were initially eligible
at the beginning of the trial before a protocol
amendment | double blind Parallel groups Sample size: 2693/2669 Primary endpoint: death, MI, ischemia-driven revascularization FU duration: 48 h | | CHAMPION-PCI, 2009 | cangrelor up front (cangrelor administered before percutaneous coronary intervention and followed by clopidogrel) (n=4367) vs. clopidogrel up front (clopidogrel followed by placebo) (n=4355) cangrelor then clopidogrel vs clopidogrel then placebo | high risk patients requiring PCI | double blind Parallel groups Sample size: 4367/4355 Primary endpoint: death, MI, ischemia-driven revascularization FU duration: 48 h | | CHAMPION PHOENIX, 2013 | bolus and infusion of cangrelor followed by 600mg clopidogrel immediately post-infusion (n=5472) vs. loading dose of 600 mg or 300 mg of clopidogrel (n=5470) | patients undergoing PCI for stable angina or for acute coronary syndromes, including ST-elevation MI | double-blind Parallel groups Sample size: 5472/5470 Primary endpoint: all-cause mortality, MI, ischemia-driven revascularization and stent thrombosis FU duration: 48 hours |
|
